Structure Therapeutics shares surge 12.46% after-hours on GLP-1 licensing deal and Phase 1 trial initiation.

Structure Therapeutics Inc. (GPCR) surged 12.46% in after-hours trading following key developments: a major GLP-1 licensing deal, initiation of a Phase 1 trial for its obesity drug ACCG-2671, and an upgraded price target from H.C. Wainwright analyst Ananda Ghosh, raising the target to $90 from $60. The licensing deal and trial progress signaled strong momentum in the company’s pipeline for oral GLP-1 therapies, while the analyst upgrade highlighted potential arbitrage opportunities and market positioning. Positive feedback from key opinion leaders on the titration strategy further reinforced confidence. Despite a 10% owner’s indirect share sale in December, the recent price action aligns with broader optimism around the company’s clinical advancements and strategic partnerships, including a $748 million public offering in December 2025. These catalysts collectively drove the after-hours rally.